SRPT

Sarepta Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-02

Figures on this page computed 2026-11-08 13:29 UTC

Last close

18.99USD

Market data, 2026-11-04

SRPT: weekly closes from 17.63 on 2025-11-07 to 18.99 on 2026-11-04, a move of +7.7%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +7.7%

Except where said otherwise: 10-K for 2025, filed 2026-03-02

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-02
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
-32.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
-14.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
0.91Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.38 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.63x

1.75x

0.88x

1.20x

0.22x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-02

Sales2.63x
Its own average over 10 years, 836.0M.
Profit1.75x
Its own average over 10 years, -408.5M.
Free cash flow0.88x
Its own average over 10 years, -350.1M.
Debt1.20x
Its own average over 9 years, 865.5M.
Price0.22x
Its own average over 11 years, 88. Market data, 2026-11-04

Sales is furthest from its own average, at 2.63 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	2,851.6	120.8
2018-12-31	5,553.1	136.0
2019-12-31	7,025.1	151.2
2020-12-31	9,963.1	160.1
2021-12-31	12,947.6	166.9
2022-12-31	17,211.1	179.8
2023-12-31	22,935.5	189.7
2024-12-31	35,085.4	221.5
2025-12-31	40,550.4	205.6

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-084144
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-084144
Reported in: USD

The filing itself

Figures behind the shape

Growth

32.4%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate32.4%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-403.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-62.5%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
Return on equity-62.5%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
Return on assets-21.3%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself

Margins

98.8%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin98.8%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
Operating margin-31.8%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
Net margin-32.5%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
Free cash flow margin-14.0%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself

Price

1.6x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-02
The filing itself
Price to book1.6x10-Q for 2025, filed 2026-08-05
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-335003
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-05
- computed
- 10-K for 2025, filed 2026-03-02
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-03-02
The filing itself
Price to sales ratio0.8x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself

Safety

0.91

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.91
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-Q for 2025, filed 2026-08-05
The filing itself
Current ratio2.3210-Q for 2025, filed 2026-08-05
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-335003
Reported in
USD
- 10-Q for 2025, filed 2026-08-05
- 10-Q for 2025, filed 2026-08-05
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
Altman Z-Score-1.07
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-02
- Computed from the 10-K for 2025, filed 2026-03-02
- Computed from the 10-K for 2025, filed 2026-03-02
- Computed from the 10-K for 2025, filed 2026-03-02
- Computed from the 10-K for 2025, filed 2026-03-02

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-084144
Reported in
USD
- 10-K for 2025, filed 2026-03-02
- Computed from the 10-K for 2025, filed 2026-03-02
- 10-K for 2025, filed 2026-03-02
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.